Nordic Nanovector has dosed the first patient in its Phase Ib Archer-1 trial evaluating the safety and preliminary activity of betalutin (177Lu-satetraxetan-lilotomab) in combination with rituximab (RTX) for the treatment of patients with second-line follicular lymphoma (2L FL).

FL is a type of blood cancer and the most common of the indolent non-Hodgkin’s lymphomas.

As part of the open-label, single-arm, multi-centre trial, Nordic Nanovector aims to enrol 20-25 patients with relapsed / refractory FL who have received one or more prior therapies.

Patients will initially be treated with 10MBq/kg betalutin and 40mg lilotomab, with increased doses expected in the future.

After the betalutin dosing, patients will get four weekly doses of 375mg/m2 RTX.

“Archer-1 presents an opportunity to investigate the potential of a novel dual CD37/CD20-targeting combination approach in 2L FL patients.”

The primary objective of the dose-escalation trial is safety, while secondary objectives comprise overall response rate, duration of response, progression-free survival and overall survival.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

Nordic Nanovector CEO Eduardo Bravo said: “Archer-1 presents an opportunity to investigate the potential of a novel dual CD37/CD20-targeting combination approach in 2L FL patients.

“If the preclinical results translate to patients, this may indicate a new way to administer biologic therapy in FL.”

Betalutin is an anti-CD37 antibody (lilotomab) designed to target tumours.

The solution demonstrated improved efficacy and safety in the first part of the Phase I/II LYMRIT 37-01 clinical trial in relapsed / refractory follicular lymphoma (R/R FL).

RTX is developed to target CD20. The monoclonal antibody is used to treat patients with newly diagnosed or relapsed FL as a single agent or in combination with chemotherapy.